202 related articles for article (PubMed ID: 37753740)
1. ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.
Bharadwaj AG; McLean ME; Dahn ML; Cahill HF; Wasson MD; Arun RP; Walker OL; Cruickshank BM; Fernando W; Venkatesh J; Barnes PJ; Bethune G; Knapp G; Helyer LK; Giacomantonio CA; Waisman DM; Marcato P
Mol Oncol; 2024 Jan; 18(1):91-112. PubMed ID: 37753740
[TBL] [Abstract][Full Text] [Related]
2. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of plasmin formation in primary breast cancer.
Chappuis PO; Dieterich B; Sciretta V; Lohse C; Bonnefoi H; Remadi S; Sappino AP
J Clin Oncol; 2001 May; 19(10):2731-8. PubMed ID: 11352966
[TBL] [Abstract][Full Text] [Related]
4. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
6. Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Chintala SK
Exp Eye Res; 2016 Feb; 143():17-27. PubMed ID: 26474495
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
9. Myosin as cofactor and substrate in fibrinolysis.
Machovich R; Ajtai K; Kolev K; Owen WG
FEBS Lett; 1997 Apr; 407(1):93-6. PubMed ID: 9141488
[TBL] [Abstract][Full Text] [Related]
10. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
Tsuboi R; Rifkin DB
Int J Cancer; 1990 Jul; 46(1):56-60. PubMed ID: 2142142
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen and plasmin activity in patients with coronary artery disease.
Drinane MC; Sherman JA; Hall AE; Simons M; Mulligan-Kehoe MJ
J Thromb Haemost; 2006 Jun; 4(6):1288-95. PubMed ID: 16706973
[TBL] [Abstract][Full Text] [Related]
12. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Lijnen HR; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1035-45. PubMed ID: 9672063
[TBL] [Abstract][Full Text] [Related]
13. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
14. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
15. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
Bi Oh S; Suh N; Kim I; Lee JY
Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
[TBL] [Abstract][Full Text] [Related]
16. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
17. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Sharma MC; Sharma M
Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis of highly polysialylated NCAM by the tissue plasminogen activator-plasmin system in rats.
Endo A; Nagai N; Urano T; Ihara H; Takada Y; Hashimoto K; Takada A
Neurosci Lett; 1998 Apr; 246(1):37-40. PubMed ID: 9622202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
